Enhanced Regulatory Compliance through Upgrading the Valladolid Facility

Global CDMO Curia has completed a $4 million investment in its sterile API production facility at its Valladolid, Spain site. This investment focuses on remodeling two aseptic suites to meet the requirements of the European Union's GMP Annex 1. Specifically, the company has transitioned to a fully closed manufacturing system and introduced state-of-the-art isolators to ensure the stability of steroids and hormones, which are highly susceptible to contamination. This strategic decision aims to eliminate technical gaps and commercialization risks arising from fragmented manufacturing processes.

Expanding Steroid Market Driven by Aging Population and Increased Chronic Diseases

The market for steroids and hormone replacement therapy (HRT) is experiencing strong growth due to the accelerating aging population and the increasing number of autoimmune disease patients. The global HRT market is expected to reach approximately $39.64 billion by 2025, and the steroid hormone API market, a key raw material, is projected to grow to approximately $6.06 billion by 2034. To capture this market, companies must overcome high technical manufacturing barriers. Most steroid raw materials are susceptible to heat and radiation, making final sterilization impossible. Therefore, having strong aseptic processing capabilities is a key factor in selecting a CDMO partner.

Building an End-to-End Partnership Covering from Clinical to Commercial Stages

From the perspective of biotech companies in the clinical development stage, Curia's flexible batch production capabilities and lifecycle management are attractive alternatives. By working with a single partner from preclinical to Phase 1-3 clinical trials and global commercial production, companies can reduce development costs and accelerate time to market. Curia has demonstrated its expertise by quickly stabilizing the manufacturing process of an existing steroid product for a multinational pharmaceutical company that was facing supply chain disruptions due to yield decline and by supporting the company in obtaining regulatory approval. This track record demonstrates excellent reliability in the high-value raw material pharmaceutical market, where ensuring process continuity is essential.

Enhanced Financial Stability and Competitiveness through Apollo's Recapitalization Deal

From a financial perspective, Curia has undergone a major restructuring of its financial structure by concluding a recapitalization transaction led by Apollo Global Management in July 2026. In this transaction, Apollo Fund acquired a majority stake and became the largest shareholder, significantly reducing the company's debt burden following the $1.3 billion first-lien debt refinancing in March 2025. With a stable inflow of capital, the company can continue to invest in facility upgrades and demonstrate long-term supply stability in bidding against competitors such as Lonza and Siegfried.